Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 106


Biologic and Nonbiologic Systemic Agents and Phototherapy for Treatment of Chronic Plaque Psoriasis [Internet].

Lee S, Coleman CI, Limone B, Kaur R, White CM, Kluger J, Sobieraj DM.

Rockville (MD): Agency for Healthcare Research and Quality (US); 2012 Nov.


Ultraviolet Phototherapy Management of Moderate-to-Severe Plaque Psoriasis: An Evidence-Based Analysis.

Health Quality Ontario.

Ont Health Technol Assess Ser. 2009;9(27):1-66. Epub 2009 Nov 1.


Anti-TNF agents for paediatric psoriasis.

Sanclemente G, Murphy R, Contreras J, GarcĂ­a H, Bonfill Cosp X.

Cochrane Database Syst Rev. 2015 Nov 24;(11):CD010017. doi: 10.1002/14651858.CD010017.pub2. Review.


Comparative effectiveness of commonly used systemic treatments or phototherapy for moderate to severe plaque psoriasis in the clinical practice setting.

Gelfand JM, Wan J, Callis Duffin K, Krueger GG, Kalb RE, Weisman JD, Sperber BR, Stierstorfer MB, Brod BA, Schleicher SM, Bebo BF Jr, Troxel AB, Shin DB, Steinemann JM, Goldfarb J, Yeung H, Van Voorhees AS.

Arch Dermatol. 2012 Apr;148(4):487-94. doi: 10.1001/archdermatol.2012.370.


Venous Thromboembolism Prophylaxis in Orthopedic Surgery [Internet].

Sobieraj DM, Coleman CI, Tongbram V, Lee S, Colby J, Chen WT, Makanji SS, Ashaye A, Kluger J, White CM.

Rockville (MD): Agency for Healthcare Research and Quality (US); 2012 Mar.


TNF-alpha inhibitors for ankylosing spondylitis.

Maxwell LJ, Zochling J, Boonen A, Singh JA, Veras MM, Tanjong Ghogomu E, Benkhalti Jandu M, Tugwell P, Wells GA.

Cochrane Database Syst Rev. 2015 Apr 18;(4):CD005468. doi: 10.1002/14651858.CD005468.pub2. Review.


Biologics or tofacitinib for people with rheumatoid arthritis naive to methotrexate: a systematic review and network meta-analysis.

Singh JA, Hossain A, Mudano AS, Tanjong Ghogomu E, Suarez-Almazor ME, Buchbinder R, Maxwell LJ, Tugwell P, Wells GA.

Cochrane Database Syst Rev. 2017 May 8;5:CD012657. doi: 10.1002/14651858.CD012657. Review.


Etanercept and efalizumab for the treatment of psoriasis: a systematic review.

Woolacott N, Hawkins N, Mason A, Kainth A, Khadjesari Z, Vergel YB, Misso K, Light K, Chalmers R, Sculpher M, Riemsma R.

Health Technol Assess. 2006 Nov;10(46):1-233, i-iv. Review.


Interventions for nail psoriasis.

de Vries AC, Bogaards NA, Hooft L, Velema M, Pasch M, Lebwohl M, Spuls PI.

Cochrane Database Syst Rev. 2013 Jan 31;(1):CD007633. doi: 10.1002/14651858.CD007633.pub2. Review.


Etanercept, infliximab and adalimumab for the treatment of psoriatic arthritis: a systematic review and economic evaluation.

Rodgers M, Epstein D, Bojke L, Yang H, Craig D, Fonseca T, Myers L, Bruce I, Chalmers R, Bujkiewicz S, Lai M, Cooper N, Abrams K, Spiegelhalter D, Sutton A, Sculpher M, Woolacott N.

Health Technol Assess. 2011 Feb;15(10):i-xxi, 1-329. doi: 10.3310/hta15100. Review.


Oral fumaric acid esters for psoriasis.

Atwan A, Ingram JR, Abbott R, Kelson MJ, Pickles T, Bauer A, Piguet V.

Cochrane Database Syst Rev. 2015 Aug 10;(8):CD010497. doi: 10.1002/14651858.CD010497.pub2. Review.


Comparative effectiveness of biologic agents for the treatment of psoriasis in a real-world setting: Results from a large, prospective, observational study (Psoriasis Longitudinal Assessment and Registry [PSOLAR]).

Strober BE, Bissonnette R, Fiorentino D, Kimball AB, Naldi L, Shear NH, Goyal K, Fakharzadeh S, Calabro S, Langholff W, You Y, Galindo C, Lee S, Lebwohl MG.

J Am Acad Dermatol. 2016 May;74(5):851-61.e4. doi: 10.1016/j.jaad.2015.12.017. Epub 2016 Feb 4.


Economic evaluation of systemic therapies for moderate to severe psoriasis.

Sizto S, Bansback N, Feldman SR, Willian MK, Anis AH.

Br J Dermatol. 2009 Jun;160(6):1264-72. doi: 10.1111/j.1365-2133.2008.08962.x. Epub 2008 Dec 15.


Narrow-band ultraviolet B phototherapy versus broad-band ultraviolet B or psoralen-ultraviolet A photochemotherapy for psoriasis.

Chen X, Yang M, Cheng Y, Liu GJ, Zhang M.

Cochrane Database Syst Rev. 2013 Oct 23;(10):CD009481. doi: 10.1002/14651858.CD009481.pub2. Review.


Comparative effectiveness of less commonly used systemic monotherapies and common combination therapies for moderate to severe psoriasis in the clinical setting.

Takeshita J, Wang S, Shin DB, Callis Duffin K, Krueger GG, Kalb RE, Weisman JD, Sperber BR, Stierstorfer MB, Brod BA, Schleicher SM, Robertson AD, Linn KA, Shinohara RT, Troxel AB, Van Voorhees AS, Gelfand JM.

J Am Acad Dermatol. 2014 Dec;71(6):1167-75. doi: 10.1016/j.jaad.2014.08.003. Epub 2014 Sep 24.


Treatment Strategies for Women With Coronary Artery Disease [Internet].

Dolor RJ, Melloni C, Chatterjee R, Allen LaPointe NM, Williams JB Jr, Coeytaux RR, McBroom AJ, Musty MD, Wing L, Samsa GP, Patel MR.

Rockville (MD): Agency for Healthcare Research and Quality (US); 2012 Aug.


Efficacy and tolerability of biologic and nonbiologic systemic treatments for moderate-to-severe psoriasis: meta-analysis of randomized controlled trials.

Schmitt J, Zhang Z, Wozel G, Meurer M, Kirch W.

Br J Dermatol. 2008 Sep;159(3):513-26. doi: 10.1111/j.1365-2133.2008.08732.x. Epub 2008 Jul 9. Review.


Drug Therapy for Psoriatic Arthritis in Adults: Update of a 2007 Report [Internet].

Donahue KE, Jonas D, Hansen RA, Roubey R, Jonas B, Lux LJ, Gartlehner G, Harden E, Yuen A, Thieda P, Morgan LC, Crotty K, Van Noord M.

Rockville (MD): Agency for Healthcare Research and Quality (US); 2012 Apr.


Down-titration and discontinuation strategies of tumor necrosis factor-blocking agents for rheumatoid arthritis in patients with low disease activity.

van Herwaarden N, den Broeder AA, Jacobs W, van der Maas A, Bijlsma JW, van Vollenhoven RF, van den Bemt BJ.

Cochrane Database Syst Rev. 2014 Sep 29;(9):CD010455. doi: 10.1002/14651858.CD010455.pub2. Review.


Supplemental Content

Support Center